Dual-modified cationic liposomes loaded with paclitaxel and survivin siRNA for targeted imaging and therapy of cancer stem cells in brain glioma

References

• Alama A, Orengo AM, Ferrini S, Gangemi R. (2012). Targeting cancer-initiating cell drug-resistance: a roadmap to a new-generation of cancer therapies? Drug Discov Today 17:435–42.
   PubMed Web of Science ®Google Scholar
• AlShamaileh H, Wang T, Xiang D, et al. (2017). Aptamer-mediated survivin RNAi enables 5-fluorouracil to eliminate colorectal cancer stem cells. Sci Rep 7:23.
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, McLendon RE, et al. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–60.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhang Y, Tang C, et al. (2017). Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis. Int J Pharm 529:102–15.
   PubMed Web of Science ®Google Scholar
• Cheng L, Bao S, Rich JN. (2010). Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol 80:654–65.
   PubMed Web of Science ®Google Scholar
• Chiou G-Y, Cherng J-Y, Hsu H-S, et al. (2012). Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial–mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma. J Control Release 159:240–50.
   PubMed Web of Science ®Google Scholar
• Dahan P, Martinez Gala J, Delmas C, et al. (2014). Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance. Cell Death Dis 5:e1543.
   PubMed Web of Science ®Google Scholar
• Guo J, Gao X, Su L, et al. (2011). Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 32:8010–20.
   PubMed Web of Science ®Google Scholar
• Guvenc H, Pavlyukov MS, Joshi K, et al. (2013). Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex. Clin Cancer Res 19:631.
   PubMed Web of Science ®Google Scholar
• Jianan Shen QM, Sui H, Yin Q, et al. (2014). iRGD conjugated TPGS mediates codelivery of paclitaxel and survivin shRNA for the reversal of lung cancer resistance. Mol Pharm 11:2579.
   PubMed Web of Science ®Google Scholar
• Jianxin Jiang HC, Yu C, Zhang Y, et al. (2015). The promotion of salinomycin delivery to hepatocellular carcinoma cells through EGFR and CD133 aptamers conjugation by PLGA nanoparticles. Nanomedicine 10:1863.
   PubMed Web of Science ®Google Scholar
• Kar R, Palanichamy JK, Banerjee A, et al. (2015). Survivin siRNA increases sensitivity of primary cultures of ovarian cancer cells to paclitaxel. Clin Transl Oncol 17:737.
   PubMed Web of Science ®Google Scholar
• Kitange GJ, Carlson BL, Mladek AC, et al. (2009). Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft mode. J Neurooncol 92:23.
   PubMed Web of Science ®Google Scholar
• Kreso A, Dick JE. (2014). Evolution of the cancer stem cell model. Cell Stem Cell 14:275–91.
   PubMed Web of Science ®Google Scholar
• Leon G, MacDonagh L, Finn SP, et al. (2016). Cancer stem cells in drug resistant lung cancer: targeting cell surface markers and signaling pathways. Pharmacol Therap 158:71–90.
   PubMed Web of Science ®Google Scholar
• Ren J, Shen S, Wang D, et al. (2012). The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials 33:3324–33.
   PubMed Web of Science ®Google Scholar
• Salzano G, Navarro G, Trivedi MS, et al. (2015). Multifunctional polymeric micelles co-loaded with anti-survivin siRNA and paclitaxel overcome drug resistance in an animal model of ovarian cancer. Mol Cancer Ther 14:1075.
   PubMed Web of Science ®Google Scholar
• Serena Acquati AG, Licastro Bhagat DH, et al. (2013). Epigenetic regulation of survivin by Bmi1 is cell type specific during corticogenesis and in gliomas. Stem Cells 31:190.
   PubMed Web of Science ®Google Scholar
• Shen J, Yin Q, Chen L, et al. (2012). Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer. Biomaterials 33:8613–24.
   PubMed Web of Science ®Google Scholar
• Shen S, Xia J-X, Wang J. (2016). Nanomedicine-mediated cancer stem cell therapy. Biomaterials 74:1–18.
   PubMed Web of Science ®Google Scholar
• Shigdar S, Qiao L, Zhou S-F, et al. (2013). RNA aptamers targeting cancer stem cell marker CD133. Cancer Lett 330:84–95.
   PubMed Web of Science ®Google Scholar
• Sun X, Pang Z, Ye H, et al. (2012). Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome. Biomaterials 33:916–24.
   PubMed Web of Science ®Google Scholar
• Vlaming MLH, Läppchen T, Jansen HT, et al. (2015). PET-CT imaging with [18F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug–drug interactions at the murine blood–brain barrier. Nucl Med Biol 42:833–41.
   PubMed Web of Science ®Google Scholar
• Wang H, Agarwal P, Zhao S, et al. (2015). Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells. Biomaterials 72:74–89.
   PubMed Web of Science ®Google Scholar
• Xin H, Sha X, Jiang X, et al. (2012). Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles. Biomaterials 33:8167–76.
   PubMed Web of Science ®Google Scholar
• Yang Z-Z, Li J-Q, Wang Z-Z, et al. (2014). Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials 35:5226–39.
   PubMed Web of Science ®Google Scholar
• Yu Z, Pestell TG, Lisanti MP, Pestell RG. (2012). Cancer stem cells. Int J Biochem Cell Biol 44:2144–51.
   PubMed Web of Science ®Google Scholar
• Zhao J. (2016). Cancer stem cells and chemoresistance: the smartest survives the raid. Pharmacol Ther 160:145–58.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Alakhova DY, Kabanov AV. (2013). Can nanomedicines kill cancer stem cells? Adv Drug Deliv Rev 65:1763–83.
   PubMed Web of Science ®Google Scholar